You are here: Industry Insights > gilead

News List

Supreme Court rebuffs appeals from Merck, Gilead in 2 high-profile drug battles fiercepharma
January 10, 2019
Monday was a good-news-bad-news day for Gilead Sciences at the U.S. Supreme Court, with the justices handing down multiple decisions about which appeals they would take up as they headed back to work after the holiday break.
Merck's cancer aims, Gilead's new CEO; Pfizer's cliff-free future fiercepharma
January 09, 2019
Pharma came storming out of the gate at this year's J.P. Morgan Healthcare Conference in a Monday full of deal talk, CEO ambitions and analyst assessments and prognostications.
Merck loses bid to revive $200 million Gilead verdict at US high court expressbpd
January 09, 2019
Merck had urged the Supreme Court to place limits on the doctrine of ‘unclean hands’ that can prevent plaintiffs from winning lawsuits if they acted in bad faith.
Gilead Sciences, Yuhan to treat advanced fibrosis due to NASH biospectrumasia
January 07, 2019
Gilead Sciences, Inc. and Yuhan Corporation has announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients....
With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH drug development fiercebiotech
January 02, 2019
The FDA has published draft guidance on developing NASH drugs that has implications for Gilead and the host of other companies targeting the indication.....
Gilead & Agenus form $1.8bn partnership pharmatimes
December 24, 2018
Gilead Sciences and Agenus have announced a partnership to focus on the development and commercialisation of up to five novel immuno-oncology therapies.
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
December 24, 2018
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments......
Gilead hands Scholar Rock $80M in fibrotic disease deal potentially worth $1.5B fiercebiotech
December 20, 2018
Gilead and Scholar Rock are joining forces on new drugs for fibrotic diseases that inhibit the activation of transforming growth factor beta (TGFβ).
Roche’s Daniel O’Day to become Gilead's chief executive pharmatimes
December 11, 2018
Gilead Sciences has announced that Daniel O'Day, the current chief executive (CEO) of Roche's pharmaceutical unit, will become its chief executive effective from March 1 next year.
NICE give go-ahead to Gilead's Yescarta for adults with lymphoma pharmafile
December 10, 2018
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page